Grant Award Details
- Improve safety of hiPSC derived cell therapies - further detail is below under "Comments/other issues.
Grant Application Details
- Developing induced pluripotent stem cells into human therapeutics and disease models
Human embryonic stem cells (hESCs) can undergo unlimited self-renewal and differentiate into all the cell types in the human body, and thus hold great promise for cell replacement therapy. However, one major problem for hESC-based therapy is that the cells derived from hESCs will be rejected by the recipient and can only be tolerated under persistent immunosuppression, which itself can cause cancer and infection. Recent development of induced pluripotent stem cells (iPSCs), which are generated from somatic cells of individual patient with defined factors and very similar to hESCs, could provide ideal cell source for transplantation by avoiding graft rejection in the patient. In addition, the disease-specific iPSCs can be used as human disease models for more reliable testing of the efficacy and toxicity of drugs. However, there are several major bottlenecks that prevent the development of iPSCs in human therapy and drug discovery. The overall goal of this proposal is to resolve the major bottlenecks remained in human iPSC biology to make it feasible for human therapy and drug discovery. We propose to develop safe and efficient approach to generate iPSCs from human patients. We propose to develop strategies to eliminate the risk of teratomas associated with the undifferentiated iPSCs. We propose to develop mouse model with functional human immune system to study the immune responses and tolerance during transplantation. Resolving these bottlenecks will greatly facilitate the development of hESCs into stem cell therapy and disease models for drug discovery.
Diabetes and heart diseases remain the most costly diseases in our State and Nation. In the case of diabetes, 1 of every 10 Californians (2.7 million) were afflicted with diabetes in 2007, costing the State $24.5 billion annually. There is a significant increase in the occurrence of both types of diabetes in youths under 18 years of age (0.16% of youth <18 yr have type 1 diabetes nationally). Simply put, diabetes is having devastating consequences on both those afflicted and on State/National healthcare costs, and, given the staggering rise in both occurrence and costs, diabetes possesses the potential to completely overwhelm our healthcare system. There remains an urgent and critical need for a cell-based cure of diabetes. There is hope, since transplantation of functional β cells from human donors has been validated clinically to cure diabetes.
While significant progress has been made in the derivation of functional β cells and cardiomyocytes from human ES cells, these allogenic cells will be rejected by the recipient upon transplantation unless the immune system of the recipient is persistently suppressed. However, immune suppression itself has severe consequences with significantly increased risk of cancer and infection. This problem might be resolved by the recent breakthrough in induced pluripotent stem cell (iPSCs), which can be reprogrammed from somatic cells of human patients by defined factors and thus can provide a renewable source of autologous cells for transplantation. In addition, the disease-specific iPSCs will provide the much needed disease models to more reliably predict the drug responses in humans. With our significant progress in producing iPSCs without viral vectors or permanent genetic modification, our proposed research will resolve the major bottlenecks that hinder the development of iPSCs into human therapy and drug discovery. If successful, the funding spent now on research is nominal when compared to the billions that will be saved in treatment costs and the improved quality of life for patients.
- Oncogene (2018) Artemisitene suppresses tumorigenesis by inducing DNA damage through deregulating c-Myc-topoisomerase pathway. (PubMed: 29795406)
- Stem Cells (2016) Brief Report: Immune Microenvironment Determines the Immunogenicity of Induced Pluripotent Stem Cell Derivatives. (PubMed: 26439188)
- Cell Stem Cell (2015) Humanized Mice Reveal Differential Immunogenicity of Cells Derived from Autologous Induced Pluripotent Stem Cells. (PubMed: 26299572)
- Stem Cell Reports (2014) Mouse SCNT ESCs Have Lower Somatic Mutation Load Than Syngeneic iPSCs. (PubMed: 24749065)
- Stem Cells (2012) Context-Dependent Enhancement of Induced Pluripotent Stem Cell Reprogramming by Silencing Puma. (PubMed: 22311782)
- J Biol Chem (2012) A scalable approach to prevent teratoma formation of human embryonic stem cells. (PubMed: 22865887)
- Protein Cell (2012) The genomic stability of induced pluripotent stem cells. (PubMed: 22528751)
- Stem Cells (2012) Concise review: Immune recognition of induced pluripotent stem cells. (PubMed: 22419544)
- Genome Med (2012) Challenges to the clinical application of pluripotent stem cells: towards genomic and functional stability. (PubMed: 22741526)
- Nature (2011) Immunogenicity of induced pluripotent stem cells. (PubMed: 21572395)
- Regen Med (2011) Self-renewal and scalability of human embryonic stem cells for human therapy. (PubMed: 21548738)
- J Biol Chem (2011) Inhibitors of Src and focal adhesion kinase promote endocrine specification: impact on the derivation of beta-cells from human pluripotent stem cells. (PubMed: 21852242)